Japan to launch Omicron variant vaccine in Oct - report - Breaking The News

Japan to launch Omicron variant vaccine in Oct - report

5 August

1 min read

EPA-EFE/HOTLI SIMANJUNTAK

The Japanese government is planning to roll out a vaccine that will specifically target the Omicron variant of COVID-19 in October, Kyodo News reported on Friday citing sources familiar with the matter.

The sources stated that the developers of the newest version of the vaccine, American multinational pharmaceutical corporations Pfizer Inc. and Moderna Inc., will be asking for its authorization in Japan soon. One of the sources mentioned that the introduction of the new vaccine will be discussed on Monday at a health ministry panel.

The bivalent vaccine uses ingredients that have already been used to create previous COVID-19 shots, mixing them with components from the BA.1 subtype of the Omicron variant.

coronavirus vaccine pfizer moderna omicron variant

Related Stocks

Moderna

Pfizer

Moderna's Q3 revenue slumps 45% to $1.0 billion

6 November

Moderna Inc. revealed on Thursday that its total revenue for the third quarter of fiscal 2025 landed at $1.0 billion, declining 45% from the same period a year ago. The drop was largely attributed to an $847 million, or 47%, fall in net product sales, primarily reflecting reduced demand for COVID vaccines.In the reported period, the biotechnology giant reported a $200 million net loss, compared with a profit of $13 million a year earlier. Its diluted loss per share...

Pfizer, Novo Nordisk said to raise bids for Metsera

4 November

Pfizer and Novo Nordisk both raised their bids for US biotech Metsera, escalating one of the fiercest takeover battles in the obesity-drug sector. The Financial Times reported on Tuesday that the improved offers from both companies are expected to be disclosed in a regulatory filing later in the day.Novo Nordisk last week topped Pfizer's earlier agreement with a proposal worth up to $9 billion, triggering a legal and commercial standoff between the two...

Pfizer reports Q3 sales of $16.7 billion, down 6%

4 November

Pfizer Inc. announced on Tuesday that its revenue for the third quarter of 2025 fell by 6% annually to $16.7 billion. Net income dropped 21% to $3.5 billion, while the diluted earnings per share (EPS) also lost 21% year-on-year, landing at $0.62. The pharma giant reaffirmed its full-year 2025 revenue guidance of $61 billion to $64 billion and raised its diluted EPS outlook to between $3 and $3.15."I am proud of Pfizer's leadership as the first in our industry to reach an...

Pfizer files second lawsuit against Metsera, Novo Nordisk

3 November

Pfizer Inc. said on Monday that it filed a second lawsuit against Metsera Inc., its controlling stockholders, and Novo Nordisk A/S, claiming that Novo Nordisk conspired with Metsera and engaged in anticompetitive behavior when it proposed to acquire it. Pfizer first struck a deal to buy Metsera in September, but the obesity drug company then received an offer from Novo Nordisk last week and deemed it superior to Pfizer's. Pfizer then sued both companies on...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.